NIKKEI 225
40,580.76 +506.07 (+1.26%) HANG SENG
17,978.57 +209.43 (+1.18%) CRUDE OIL
83.04 +0.23 (+0.28%) GOLD FUTURES
2,364.10 +30.70 (+1.32%) DOW
39,308.00 -23.85 (-0.06%) Bitcoin GBP
47,375.79 -1,154.09 (-2.38%)
IOVA Jan 2025 6.000 put
- Simply Wall St.
Unveiling Three US Growth Companies With High Insider Ownership
As the U.S. stock market shows signs of resilience with key indices like the Nasdaq and S&P 500 posting gains, investors are keenly observing market trends and economic indicators for strategic opportunities. In this climate, growth companies with high insider ownership can be particularly compelling, as significant insider stakes often signal confidence in the company's future prospects from those who know it best.
- GlobeNewswire
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, submitted a marketing authorization
- GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 20, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 187,650 shares of Iovance’s common stock to forty-three new,
